Τίτλος:
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III
trial of cemiplimab, an anti-programmed death (PD)-1, versus
investigator's choice (IC) chemotherapy in >= 2 line recurrent or
metastatic cervical cancer
Συγγραφείς:
Tewari, K. S.
Monk, B. J.
Oaknin, A.
Lheureux, S. and
Zagouri, F.
Rischin, D.
Hasegawa, K.
Kim, Y. M.
Pereira,
R.
Sadozye, A.
Wang, P. H.
Lisyanskaya, A.
Samouelian,
V.
Kim, H. S.
Zambrano, M.
Yi, S.
Li, J.
Feng, M.
and Mathias, M.
Fury, M. G.
Lowy, I.
Vergote, I.
